Phase 2a study results in binge eating disorder
Allschwil, Switzerland – May 10, 2022
Idorsia Ltd (SIX: IDIA) today announced that ACT-539313, a selective orexin-1 receptor antagonist, did not show an improvement over placebo in reducing the number of binge eating days per week in adult patients with moderate to severe binge eating disorder – the primary endpoint was therefore not met. ACT-539313 was very well tolerated over the treatment period of 12 weeks.
Alberto Gimona, Head of Global Clinical Development of Idorsia, commented:
“Assessing pharmaceutical intervention in disorders such as binge eating, when we target modification of the behaviors underpinning the disorder is very challenging. The result is obviously disappointing for the team and investigators who flawlessly executed the study, and of course for the patients affected by this disorder. The study confirmed the encouraging safety profile seen in the pharmacology studies, but it is clear that we will not pursue the binge eating disorder indication.”
The company will now fully analyze the data and publish the results of the study in scientific literature in due course.
Notes to the editor
About the Phase 2 study
In the study, 136 patients were randomized to receive either ACT-539313 at a dose of 100 mg twice daily, or placebo in a 1:1 ratio over a 12‑week treatment period. The primary efficacy endpoint was the change from baseline to Week 12 in the number of binge eating days per week. A binge eating day was defined as a day with at least one confirmed binge eating episode. The study also assessed the effect of ACT-539313 in modulating behavioral features that contribute to the psychopathology in BED, in addition to reducing the frequency of binge eating.
ACT-539313 is a potent, brain-penetrating, selective orexin 1 receptor antagonist. Preclinical studies have shown that orexins play a role in driving compulsive binge-like consumption, and ACT-539313 reduced binge-like eating behavior in animal models.
In the Phase 1 studies, ACT-539313 was well tolerated at single oral doses of up to and including 400 mg and at multiple oral doses of up to and including 200 mg twice daily for 10 days in healthy volunteers.
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options. Idorsia has a broad portfolio of innovative drugs in the pipeline, an experienced team of professionals covering all disciplines from bench to bedside, state-of-the-art facilities, and a strong balance sheet – the ideal constellation to translate R&D efforts into business success.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017 and has over 1,200 highly qualified specialists dedicated to realizing our ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
firstname.lastname@example.org – email@example.com – www.idorsia.com
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nextensa NV/SA : Shares repurchase26.5.2022 17:40:00 CEST | Press release
PRESS RELEASE REGULATED INFORMATION Brussels, 26 May 2022 – 5.40 PM CEST Nextensa NV/SA : Shares repurchase In accordance with article 8:4 of the Royal Decree of 29 April 2019 in execution of the Belgian Code of Companies and Associations, Nextensa announces that in the period between May 19, 2022 and May 25, 2022 included it has repurchased 1,889 treasury shares on Euronext Brussels as part of its announced share buy-back program1. The shares were repurchased at an average price (rounded) of € 68.00 per share. This share repurchase transaction was carried out to cover the purchase plans for the benefit of the executive management of Nextensa, and this within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders on 19 July 2021. Detailed operations per day DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)19/05/202245067.8667.7067.9030,535.0020/05/202245068.4868.4068.9030,8
Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons26.5.2022 15:00:33 CEST | Press release
26 May 2022 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 24 May 2022, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 3,130 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 48,175 shares, representing 0.13% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Paul Meader 2) Sarah Kingwell 2 Reason for the notification a) Position/status 1) Director and Chairman 2) PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platfor
Mandalay Resources Corporation tillkännager resultatet av årsstämman26.5.2022 14:41:34 CEST | Pressemelding
TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att tillkännage resultaten från årsstämman (”mötet”) som hölls virtuellt idag. Alla resolutioner som presenterades vid mötet godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 67,63 % av de totalt utestående aktierna på avstämningsdagen. Val av styrelseledamöter Antalet styrelseledamöter var oförändrat med sju ledamöter och var och en av de sju nominerade som fanns listade i bolagsledningens informationsutskick från den 14 april 2022 återvaldes till bolagsstyrelsen. Abraham Jonker fortsätter som oberoende samordnande ledamot och Bradford Mills fortsätter som ordförande. Resultaten av rösterna genom ombud anges nedan. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94533,7750.055Dominic Duff
Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release
Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release
– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a